Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664004 | 1.00 | MGLL (0.49) | MGLLPDK1PDK2PDK3PDK4 | |
| SCHEMBL7968974 | 1.00 | MGLL (0.49) | MGLLPDK1PDK2PDK3PDK4 | |
| SCHEMBL1704091 | 0.89 | PTGDR2 (0.52) | MGLLPTGDR2CCR1GPR119 | |
| SCHEMBL4625997 | 0.89 | PTGDR2 (0.52) | MGLLPTGDR2CCR1GPR119 | |
| SCHEMBL17821461 | 0.89 | ACHE (0.50) | CHRM4 | |
| SCHEMBL29269210 | 0.89 | CCR1 (0.47) | MGLLPTGDR2NR1H2NR1H3CCR1 | |
| SCHEMBL29269208 | 0.89 | CCR1 (0.47) | MGLLPTGDR2NR1H2NR1H3CCR1 | |
| SCHEMBL27019075 | 0.89 | AGTR2 (0.46) | AGTR2NR1H2NR1H3GPR119 | |
| SCHEMBL29269207 | 0.89 | CCR1 (0.47) | MGLLPTGDR2NR1H2NR1H3CCR1 | |
| SCHEMBL13954894 | 0.89 | PTGDR2 (0.52) | MGLLPTGDR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132120-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2026-05-14 | — | — | US | disclosed |
| US-12545657-B2 | Small-molecule modulators of the orphan nuclear receptor TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-29 | — | — | US | disclosed |
| CN-117377664-A | Small molecule modulators of orphan nuclear receptor TLX | 贝勒医学院 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4267561-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | Baylor College of Medicine (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140643-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2017182418-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | WO | disclosed |
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2007135427-A1 | 1,4-DISUBSTITUTED PIPERAZINE AND 1,4-DISUBSTITUTED AZEPANE AS 11 -BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-6291464-B1 | POTENTIATION OF THE CHOLINERGIC ACTIVITY; THERAPEUTIC TREATMENT OF AMNESIA, DEMENTIA OR SENILE DEMENTIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0727421-A1 | Agents for improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5026853-A | Sleep and cardiovascular disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-06-25 | — | — | US | disclosed |
| US-4968684-A | N-ARYL-PIPERAZINEALKANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-06 | — | — | US | disclosed |
| US-4880808-A | SEDATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-11-14 | — | — | US | disclosed |
| EP-0285219-A2 | Method of improving sleep | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545657-B2 | Small-molecule modulators of the orphan nuclear receptor TLX | NR2E1, NR2C2, NR0B1 | MGLL 3155/4885PDK1 4439/4885PDK2 4650/4885 |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | NR2E1, NR2E3, NR4A2 | MGLL 3885/4885PDK1 3942/4885PDK2 3173/4885 |
| US-20260132120-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | NR2E1, NR0B1, NR2C2 | MGLL 3166/4885PDK1 4337/4885PDK2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.